3E04305Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach
- Billable / Specific Code
3E04305 is a billable ICD-10-PCS procedure code for Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | 3 | Administration |
| 2 | Body System | E | Physiological Systems and Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodySystem/Region | 4 | Central Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Substance | 0 | Antineoplastic |
| 7 | Qualifier | 5 | Other Antineoplastic |
In the ICD-10-PCS Alphabetic Index
These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:
Clinical Classification (CCSR)
AHRQ groups this procedure code into these clinical categories.
Convert to ICD-9-PCS
Closest ICD-9-PCS equivalents for this code under the General Equivalence Mappings.
Code History
- XW04358 — Introduce Mosunetuzumab in Central Vein, Perc, New Tech 8
- XW04368 — Introduce Afamitresgene in Central Vein, Perc, New Tech 8
- XW04378 — Introduce Tabelecleucel in Central Vein, Perc, New Tech 8
- XW04387 — Introduce Lurbinectedin in Central Vein, Perc, New Tech 7
- XW0439A — Introduce Odronextamab in Central Vein, Perc, New Tech 10
- XW043B3 — Introduce cytarab/daunorub in Central Vein, Perc, New Tech 3
- XW043C3 — Introduce Auto CAR T cell in Central Vein, Perc, New Tech 3
- XW043CA — Introduce Zanidatamab in Central Vein, Perc, New Tech 10
- XW043D6 — Introduce Atezolizumab in Central Vein, Perc, New Tech 6
- XW043NA — Introduce Tarlatamab-dlle in Central Vein, Perc, New Tech 10
- XW043P9 — Introduce Glofitamab in Central Vein, Perc, New Tech 9
- XW043Q5 — Introduce Tagraxofusp-erzs in Central Vein, Perc, New Tech 5
- XW043S5 — Introduce Iobenguane I-131 in Central Vein, Perc, New Tech 5
- XW24346 — Transfuse Brexcab Autoleuc in Central Vein, Perc, New Tech 6
- XW24376 — Transfuse Lisocab Maraleuc in Central Vein, Perc, New Tech 6
Similar Procedure Codes
Questions About 3E04305
Is 3E04305 a billable code?
Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach on inpatient claims from October 1, 2026 through September 30, 2027.
What do the characters in 3E04305 mean?
The code breaks down character by character: the 1st character 3 is the Section (Administration); the 2nd character E is the Body System (Physiological Systems and Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodySystem/Region (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character 0 is the Substance (Antineoplastic); the 7th character 5 is the Qualifier (Other Antineoplastic).
What is the ICD-9-PCS equivalent of 3E04305?
Under the General Equivalence Mappings, Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach crosswalks to ICD-9-PCS 39.96 (Total body perfusion) and 99.25 (Injection or infusion of cancer chemotherapeutic substance). The mapping is approximate, so confirm it fits the documentation.
